Navigation Links
Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress

Nasalfent shows clinically meaningful pain relief within 5 minutes of dosing and is well-tolerated

READING, England, 7 June 2007 - Archimedes Pharma Ltd ("Archimedes"), a European specialty pharmaceutical company, today presented new clinical data from a Phase II study of Nasalfent(r), an innovative fentanyl citrate nasal spray aimed at providing a fast, effective and convenient treatment for breakthrough cancer pain. Data were presented at the 10th Congress of the European Association for Palliative Care (EAPC) in Budapest showing that Nasalfent can give significant, clinically meaningful levels of pain relief and a reduction in pain intensity within 5 minutes of dosing.

The open-label, multi-centre study, was conducted in two parts - the first to establish an effective dose for each patient, followed by an efficacy phase in which the dose identified in part one was evaluated using a series of measures for pain relief. Statistically significant improvements from baseline in pain intensity and onset of pain relief were seen within five minutes of dosing (both p<0.05) in the 15 patients included in the efficacy analysis. All patients experienced at least one episode with meaningful pain relief and in the 55 breakthrough cancer pain episodes assessed, some degree of pain relief was recorded in 96% and clinically meaningful pain relief in 73%.

All doses of Nasalfent from 25mcg to 800mcg were well-tolerated, with no significant nasal findings or symptoms of irritation seen at any dose. In a patient satisfaction survey, 77% rated the product as 'good', 'very good' or 'excellent'.

Principal Investigator Dr Geoff Davis, Medical Director of Palliative Care, St Joseph's Care Group, Thunder Bay, Ontario, Canada said: "Breakthrough cancer pain is a significant clinical problem which requires a drug with a fast and reliable onset of action, together with ease of use and high patient acceptabilit
'"/>




Page: 1 2 3

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
(Date:8/28/2015)... , August 28, 2015 ... to reach USD 49.12 billion by 2020, growing at ... to a new report by Grand View Research, Inc. ... CAGR of 49.7% from 2014 to 2020. ... aging population along with rising incidences of chronic diseases ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
Breaking Medicine Technology:Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... ELKRIDGE, Md., Dec. 8, 2011  Global performance improvement solutions ... subsidiary of GP Strategies Corporation (NYSE: GPX ... honored with a Platinum MarCom Award for Excellence in ... (Logo:  http://photos.prnewswire.com/prnh/20110404/MM77341LOGO-b ) ...
... today the launch of its new Posture+ sitting device, ... nearly 65 millions Americans traveling this holiday season. With ... their lifetime, this newest addition to the BackJoy product ... help travelers combat the problems associated with long-term sitting. ...
Cached Medicine Technology:GP's PerformTech Division Receives Prestigious MarCom Award 2GP's PerformTech Division Receives Prestigious MarCom Award 3BackJoy's Posture+ Device Aims to Rid the Holidays of Back Pain 2BackJoy's Posture+ Device Aims to Rid the Holidays of Back Pain 3
(Date:8/28/2015)... , ... August 28, 2015 , ... The newest therapy ... be available for general use any time soon, according to educational website Surviving Mesothelioma. ... therapy that received orphan drug designation for mesothelioma last week from the FDA, will ...
(Date:8/28/2015)... Indianapolis, IN (PRWEB) , ... August 28, 2015 ... ... employee benefits advisory organization, is pleased to welcome TJS Insurance Group as its ... to employees and clients guides them and keeps them focused on their goals. ...
(Date:8/28/2015)... ... ... External Counterpulsation, also known as ECP or EECP, is a proven treatment ... ECP) machines with a full clinic licence to help people prevent and reverse heart ... prevent and reverse heart disease through its evidence-based integrative approach to heart ...
(Date:8/28/2015)... ... August 28, 2015 , ... Yisrayl Hawkins, Pastor and ... and pleads for swift actions to be taken in order to ease the ... , Yisrayl says scientists have yet to understand fully the real cause of global ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked PREVENT Life ... of the nation’s fastest-growing private companies. The list was unveiled online at Inc.com and ... over the last three years, PREVENT ranks higher on the list than any other ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... may be beneficial in preventing severe long-term disability in multiple ... treatment for the chronic progressive phase of MS, when serious ... Children's Hospital Boston study appearing in the Journal of Neuroscience, ... type of vitamin B3 known as nicotinamide cut the risk ...
... help reduce Alzheimer's disease, says a study on mice, but ... findings apply to people.// ,Jun Wang and other researchers ... mice with genes that order the production of amyloid-beta protein, ... reported the online edition of science magazine WebMD. ...
... the basic purpose of a sunscreen lotion as well as ... well on the threshold of a discovery; Scientists have found ... the fair skin people from tanning as well as guard ... David E. Fisher, director of the Melanoma Program at the ...
... 80% of people suffering from severe chronic lung disease ... of it.// ,Chronic Bronchitis and Emphysema constitute the ... lung tissue by smoking can lead to the development ... ,Professor Robert West, director of tobacco studies at Cancer ...
... particularly those with high levels of low-density lipoprotein ... according to a study in the September 20 ... specific class of lipoprotein particles found in human ... according to background information in the article. Studies ...
... kidney cancer has been rising over the last two decades, ... Center shows// that this increase is driven largely by the ... the rising incidence has been paralleled by greater use of ... fewer people dying. ,“With increased early detection and treatment ...
Cached Medicine News:Health News:Vitamin Shots to Combat MS Pain 2Health News:80% of lung disease remains ‘undiagnosed’. 2Health News:High Levels of Lipoprotein(a) in Women is Associated With Cardiovascular Risk 2Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 2Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 3
The Onyx® 9500 worlds first self-contained digital fingertip pulse oximeter incorporates the electronics and the sensor into one unit....
Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
... The Invacare Digital Pulse ... and pulse strength. It is ... measurements on challenging patients. The ... other artifacts, informs the operator ...
Rad-9™...
Medicine Products: